{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:56:18Z","timestamp":1793228178006,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01441-z","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:32:57Z","timestamp":1783758777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies"],"prefix":"10.1007","volume":"28","author":[{"given":"Isabela C.","family":"Bitencourt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Zimerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Marston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"3","key":"1441_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/MOL.0000000000000290","volume":"27","author":"W Dijk","year":"2016","unstructured":"Dijk W, Kersten S. Regulation of lipid metabolism by angiopoietin-like proteins. Curr Opin Lipidol. 2016;27(3):249\u201356.","journal-title":"Curr Opin Lipidol"},{"issue":"39","key":"1441_CR2","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","volume":"44","author":"E Bjornson","year":"2023","unstructured":"Bjornson E, Adiels M, Taskinen MR, Burgess S, Rawshani A, Boren J, et al. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study. Eur Heart J. 2023;44(39):4186\u201395.","journal-title":"Eur Heart J"},{"issue":"4","key":"1441_CR3","doi-asserted-by":"publisher","first-page":"E493","DOI":"10.1152\/ajpendo.00195.2021","volume":"321","author":"KL Sylvers-Davie","year":"2021","unstructured":"Sylvers-Davie KL, Davies BSJ. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. Am J Physiol Endocrinol Metab. 2021;321(4):E493\u2013508.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"1441_CR4","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","volume":"61","author":"RC Adam","year":"2020","unstructured":"Adam RC, Mintah IJ, Alexa-Braun CA, Shihanian LM, Lee JS, Banerjee P, et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J Lipid Res. 2020;61(9):1271\u201386.","journal-title":"J Lipid Res"},{"issue":"3","key":"1441_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"16","key":"1441_CR6","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054\u201363.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1441_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","volume":"374","author":"FE Dewey","year":"2016","unstructured":"Dewey FE, Gusarova V, O\u2019Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123\u201333.","journal-title":"N Engl J Med"},{"issue":"8","key":"1441_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320.","journal-title":"N Engl J Med"},{"issue":"24","key":"1441_CR9","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383(24):2307\u201319.","journal-title":"N Engl J Med"},{"issue":"10489","key":"1441_CR10","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","volume":"405","author":"KK Ray","year":"2025","unstructured":"Ray KK, Oru E, Rosenson RS, Jones J, Ma X, Walgren J, et al. Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2025;405(10489):1594\u2013607.","journal-title":"Lancet"},{"issue":"10","key":"1441_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","volume":"391","author":"RS Rosenson","year":"2024","unstructured":"Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):913\u201325.","journal-title":"N Engl J Med"},{"issue":"3","key":"1441_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson RS, Gaudet D, Ballantyne CM, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29(3):729\u201337. https:\/\/doi.org\/10.1038\/s41591-023-02222-w.","journal-title":"Nat Med"},{"issue":"18","key":"1441_CR13","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145(18):1377\u201386.","journal-title":"Circulation"},{"issue":"8","key":"1441_CR14","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/s41591-025-03830-4","volume":"31","author":"D Gaudet","year":"2025","unstructured":"Gaudet D, Gonciarz M, Shen X, Leohr JK, Beyer TP, Day JW, et al. Targeting the angiopoietin-like protein 3\/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial. Nat Med. 2025;31(8):2632\u201339.","journal-title":"Nat Med"},{"issue":"10493","key":"1441_CR15","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(25)00825-6","volume":"405","author":"BB Cummings","year":"2025","unstructured":"Cummings BB, Joing MP, Bouchard PR, et al. Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b\/2a clinical studies. Lancet. 2025;405(10493):1923\u201334.","journal-title":"Lancet"},{"issue":"3","key":"1441_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1172\/JCI16146","volume":"111","author":"W Jin","year":"2003","unstructured":"Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest. 2003;111(3):357\u201362.","journal-title":"J Clin Invest"},{"key":"1441_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.02.640965","author":"O White","year":"2025","unstructured":"White O, Aligabi Z, Burks KH, et al. Endothelial lipase facilitates low-density lipoprotein (LDL) uptake in LDL receptor deficiency by a heparan sulfate proteoglycan-dependent mechanism. Preprint bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.03.02.640965. 2025.03.02.640965. Published 2025 May 26.","journal-title":"Preprint bioRxiv"},{"key":"1441_CR18","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.jlr.2021.100150","volume":"62","author":"S Kersten","year":"2021","unstructured":"Kersten S. Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism. J Lipid Res. 2021;62:100150.","journal-title":"J Lipid Res"},{"issue":"4","key":"1441_CR19","doi-asserted-by":"publisher","first-page":"150272","DOI":"10.1098\/rsob.150272","volume":"6","author":"R Zhang","year":"2016","unstructured":"Zhang R. The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking. Open Biol. 2016;6(4):150272.","journal-title":"Open Biol"},{"issue":"8","key":"1441_CR20","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1194\/jlr.RA120000781","volume":"61","author":"YQ Chen","year":"2020","unstructured":"Chen YQ, Pottanat TG, Siegel RW, Ehsani M, Qian YW, Zhen EY, et al. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids. J Lipid Res. 2020;61(8):1203\u201320.","journal-title":"J Lipid Res"},{"issue":"6","key":"1441_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MOL.0000000000000789","volume":"32","author":"S Kersten","year":"2021","unstructured":"Kersten S. ANGPTL3 as therapeutic target. Curr Opin Lipidol. 2021;32(6):335\u201341.","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"1441_CR22","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1074\/jbc.M808477200","volume":"284","author":"L Shan","year":"2009","unstructured":"Shan L, Yu XC, Liu Z, Hu Y, Sturgis LT, Miranda ML, et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol Chem. 2009;284(3):1419\u201324.","journal-title":"J Biol Chem"},{"issue":"23","key":"1441_CR23","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","volume":"363","author":"K Musunuru","year":"2010","unstructured":"Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"1441_CR24","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1161\/ATVBAHA.111.238766","volume":"32","author":"D Noto","year":"2012","unstructured":"Noto D, Cefalu AB, Valenti V, Fayer F, Pinotti E, Ditta M, et al. Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia. Arterioscler Thromb Vasc Biol. 2012;32(3):805\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"1441_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cmet.2010.11.002","volume":"12","author":"L Lichtenstein","year":"2010","unstructured":"Lichtenstein L, Mattijssen F, de Wit NJ, Georgiadi A, Hooiveld GJ, van der Meer R, et al. Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 2010;12(6):580\u201392.","journal-title":"Cell Metab"},{"key":"1441_CR26","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1038\/s41467-018-04611-z","volume":"9","author":"V Gusarova","year":"2018","unstructured":"Gusarova V, O\u2019Dushlaine C, Teslovich TM, et al. Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes. Nat Commun. 2018;9:2252. https:\/\/doi.org\/10.1038\/s41467-018-04611-z.","journal-title":"Nat Commun"},{"issue":"28","key":"1441_CR27","doi-asserted-by":"publisher","first-page":"11766","DOI":"10.1073\/pnas.0705041104","volume":"104","author":"U Desai","year":"2007","unstructured":"Desai U, Lee EC, Chung K, Gao C, Gay J, Key B, et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci U S A. 2007;104(28):11766\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1441_CR28","doi-asserted-by":"publisher","first-page":"100237","DOI":"10.1016\/j.jlr.2022.100237","volume":"63","author":"M Deng","year":"2022","unstructured":"Deng M, Kutrolli E, Sadewasser A, Michel S, Joibari MM, Jaschinski F, Olivecrona G, Nilsson SK, Kersten S. ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy. J Lipid Res. 2022;63(7):100237. https:\/\/doi.org\/10.1016\/j.jlr.2022.100237 . Epub 2022 Jun 3. PMID: 35667416; PMCID: PMC9270256.","journal-title":"J Lipid Res"},{"issue":"48","key":"1441_CR29","doi-asserted-by":"publisher","first-page":"19751","DOI":"10.1073\/pnas.1217552109","volume":"109","author":"F Quagliarini","year":"2012","unstructured":"Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A. 2012;109(48):19751\u201356.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1441_CR30","doi-asserted-by":"publisher","first-page":"120556","DOI":"10.1016\/j.atherosclerosis.2025.120556","volume":"412","author":"Y Lin","year":"2026","unstructured":"Lin Y, Wang D, Li D, Zhang F, Zhu Q, Bao X, Zhang N, et al. The role of ANGPTL8 in metabolism and cardiovascular diseases: consensus and controversy. Atherosclerosis. 2026;412:120556.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1441_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","volume":"223","author":"FJ Raal","year":"2012","unstructured":"Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262\u201368.","journal-title":"Atherosclerosis"},{"issue":"9","key":"1441_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","volume":"36","author":"B Sjouke","year":"2015","unstructured":"Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJG, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2015;36(9):560\u201365.","journal-title":"Eur Heart J"},{"issue":"32","key":"1441_CR33","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. Eur Heart J. 2014;35(32):2146\u201357.","journal-title":"Eur Heart J"},{"issue":"27","key":"1441_CR34","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","volume":"45","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Greber-Platzer S, Reeskamp LF, Iannuzzo G, Rosenson RS, Saheb S, et al. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024;45(27):2422\u201334.","journal-title":"Eur Heart J"},{"issue":"36","key":"1441_CR35","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","volume":"36","author":"A Wiegman","year":"2015","unstructured":"Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425\u201337.","journal-title":"Eur Heart J"},{"issue":"5","key":"1441_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","volume":"149","author":"A Wiegman","year":"2024","unstructured":"Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation. 2024;149(5):343\u201353.","journal-title":"Circulation"},{"issue":"2","key":"1441_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S2213-8587(25)00290-6","volume":"14","author":"FJ Raal","year":"2026","unstructured":"Raal FJ, Bergeron J, Gaudet D, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2026;14(2):123\u201336. https:\/\/doi.org\/10.1016\/S2213-8587(25)00290-6.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1441_CR38","unstructured":"Arrowhead Pharmaceuticals. Phase 3 study to evaluate the efficacy and safety of zodasiran in adolescent and adult subjects with homozygous familial hypercholesterolemia (YOSEMITE). ClinicalTrials.gov; NCT07037771. Registered 2025."},{"issue":"45","key":"1441_CR39","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478\u2013a90.","journal-title":"Eur Heart J"},{"issue":"11","key":"1441_CR40","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1210\/jc.2012-1563","volume":"97","author":"M Benn","year":"2012","unstructured":"Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97(11):3956\u201364.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1441_CR41","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacl.2019.05.004","volume":"13","author":"DJ Blom","year":"2019","unstructured":"Blom DJ, Almahmeed W, Al-Rasadi K, Azuri J, Daclin V, Kayikcioglu M, et al. Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International ChoLesterol Management Practice Study. J Clin Lipidol. 2019;13(4):594\u2013600.","journal-title":"J Clin Lipidol"},{"key":"1441_CR42","doi-asserted-by":"publisher","first-page":"117117","DOI":"10.1016\/j.atherosclerosis.2023.03.022","volume":"384","author":"MM Schreuder","year":"2023","unstructured":"Schreuder MM, Hamkour S, Siegers KE, Holven KB, Johansen AK, van de Ree MA, et al. LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: a sex- and gender-specific analysis. Atherosclerosis. 2023;384:117117.","journal-title":"Atherosclerosis"},{"issue":"11","key":"1441_CR43","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamacardio.2023.2921","volume":"8","author":"RS Rosenson","year":"2023","unstructured":"Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, et al. Longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia. JAMA Cardiol. 2023;8(11):1070.","journal-title":"JAMA Cardiol"},{"key":"1441_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04307-8","author":"GF Watts","year":"2026","unstructured":"Watts GF, Scott R, Sullivan D, et al. Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial. Nat Med. 2026;32:1432\u20131443. https:\/\/doi.org\/10.1038\/s41591-026-04307-8","journal-title":"Nat Med"},{"key":"1441_CR45","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/eurjpc\/zwae090","volume":"31","author":"A Zimerman","year":"2024","unstructured":"Zimerman A, Bergmark BA, Curto M, Ramos V, Jevne A, Bramson CR, Marston NA. Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial. Eur J Prev Cardiol. 2024;31:1216\u201323.","journal-title":"Eur J Prev Cardiol"},{"key":"1441_CR46","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/j.jacl.2023.12.001","volume":"18","author":"A Zimerman","year":"2024","unstructured":"Zimerman A, Bergmark BA, Curto M, Ramos V, Jevne A, Bramson CR, Marston NA. Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3. J Clin Lipidol. 2024;18:e261\u20138.","journal-title":"J Clin Lipidol"},{"issue":"19","key":"1441_CR47","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.jacc.2025.03.008","volume":"85","author":"X Xie","year":"2025","unstructured":"Xie X, Shi X, Zhang Y, et al. Angiopoietin-like 3 antibody therapy in patients with suboptimally controlled hyperlipidemia: a phase 2 study. J Am Coll Cardiol. 2025;85(19):1821\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.008.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"1441_CR48","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa2511778","volume":"393","author":"LJ Laffin","year":"2025","unstructured":"Laffin LJ, Nicholls SJ, Scott RS, et al. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. N Engl J Med. 2025;393(21):2119\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2511778.","journal-title":"N Engl J Med"},{"key":"1441_CR49","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1177\/2047487319871733","volume":"27","author":"SU Khan","year":"2020","unstructured":"Khan SU, Khan MU, Valavoor S, et al. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. Eur J Prev Cardiol. 2020;27:1255\u201368.","journal-title":"Eur J Prev Cardiol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01441-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01441-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01441-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:32:59Z","timestamp":1783758779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01441-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1441"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01441-z","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}